Related Experiment Video
Updated: Jun 3, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Incidental atrial fibrillation and its management
1Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH 44195, USA. salibaw@ccf.org
Insights
Atrial fibrillation (AF), a common heart rhythm disorder, significantly increases stroke risk. Prompt management and antithrombotic therapy are crucial for all AF types to prevent ischemic strokes.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia.
- AF prevalence is often underestimated due to intermittent or asymptomatic cases.
- All types of AF (paroxysmal, persistent, permanent) are potent risk factors for ischemic stroke.
Purpose of the Study:
- To review current management strategies for atrial fibrillation.
- To discuss antithrombotic therapy for stroke risk reduction in AF patients.
- To examine novel oral anticoagulants for stroke prevention in AF.
Main Methods:
- Review of existing literature on atrial fibrillation management and stroke prevention.
- Analysis of risk stratification schemes (CHADS2 and CHA2DS2-VASc).
- Evaluation of warfarin's efficacy and limitations.
- Overview of new oral anticoagulants in development.
Main Results:
- Prompt management of AF, including rate or rhythm control and antithrombotic therapy, is essential.
- Antithrombotic choice depends on stroke risk stratification.
- Warfarin is effective but has significant drawbacks (narrow therapeutic range, interactions).
- Newer oral anticoagulants offer potential advantages over warfarin.
Conclusions:
- Effective stroke risk reduction in AF requires identifying causative factors and implementing appropriate management strategies.
- Antithrombotic therapy is a cornerstone of AF management.
- Emerging oral anticoagulants show promise for improving stroke prevention in AF patients.
Abstract:
Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia, yet because AF can often be intermittent or lacking in overt symptoms, its prevalence is underestimated, and it may be diagnosed only incidentally. Because AF is a potent ischemic stroke risk factor and stroke rates are similar for paroxysmal, persistent, and permanent AF, all AF types require prompt management. This involves identifying and treating underlying causative factors, then implementing a "rate-control" or "rhythm-control" strategy. Regardless of approach, concomitant antithrombotic therapy for stroke risk reduction is recommended. Antithrombotic agent choice (acetylsalicylic acid or warfarin) depends on level of stroke risk; this review covers both the CHADS2 and CHA2DS2-VASc risk stratification schemes. Warfarin provides effective ischemic stroke prophylaxis but has numerous drawbacks, including a narrow therapeutic range, unpredictable pharmacokinetics, slow on-/offset of action, and multiple food and drug interactions. New oral anticoagulants that lack many of these drawbacks are in development. Here we review these drugs for stroke prevention in AF.
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Mitral Stenosis III: Medical Management
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Mitral Regurgitation III: Medical Management
Aortic Regurgitation III: Medical Management

